PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology Corporation stocks have been trading up by 13.08 percent amid heightened optimism over its latest clinical progress.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PDSB

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Peer-reviewed Phase 2 data in JAMA Oncology show PDS0101 plus pembrolizumab achieved a 36% objective response rate in CPS ≥1 patients versus a 19% historical benchmark, with 39.3-month median overall survival and tolerable safety in HPV16-positive recurrent/metastatic head and neck cancer.
A Nant Capital–led PIPE raised about $11.3M at roughly $0.28 per unit, with another ~$11M contingent on submitting a Phase 3 protocol for PDS0301.
Proceeds are earmarked to repay debt and push PDS0301 through late-stage development in metastatic colorectal cancer, while management seeks a partner or out-license deal for HPV immunotherapy PDS0101.
NantWorks gained a one-year exclusive option to negotiate an exclusive PDS0101 license, and Patrick Soon-Shiong plus NantBio CFO James Banaag joined the PDS Biotechnology board at the initial closing.
A fresh Schedule 13D shows a sizable new beneficial holder in PDSB, hinting at an active or potentially activist presence in the name.

Live Update At 12:32:07 EDT: On Tuesday, October 13, 2026 PDS Biotechnology Corporation stock [NASDAQ: PDSB] is trending up by 13.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PDS Biotechnology (PDSB) has gone from a sub-$1 stock to a clear momentum name on the chart. In late September 2026, PDSB was chopping around $0.72–$0.91. By early October, it briefly dipped near $0.71, then exploded to $1.35 on 2026/10/05 and kept grinding higher. As of 2026/10/13, PDSB closed at $1.715, more than doubling in a few weeks.

Intraday action tells the same story. On the latest trading day, PDSB opened near $1.43, pulled back slightly, then trended up all morning. Buyers stepped in around $1.60–$1.65 and pushed the stock to an intraday high near $1.79 before consolidating in the low $1.70s. That’s classic strong-trend behavior: higher lows, controlled pullbacks, and steady bids.

More Breaking News

Under the hood, PDSB is still a cash-burning micro-cap biotech. The latest quarterly report shows about $5.6M in cash, negative working capital, and operating cash outflows around $2.8M for the quarter. Return on equity and assets are deeply negative, and book value is underwater. For traders, that means dilution and financing risk stay front and center. The recent PIPE helps extend runway, but it came at a steep price. PDSB is a story-driven, catalyst-driven trade, not a balance-sheet powerhouse.

Why Traders Are Watching PDSB Now

PDS Biotechnology has dropped two big narrative bombs at once: strong mid-stage clinical data and a highly dilutive financing wrapped in strategic partnerships. That combination is exactly what catches momentum traders’ eyes.

First, the science. PDSB reported peer-reviewed Phase 2 results in JAMA Oncology for its HPV16-targeted immunotherapy PDS0101 with pembrolizumab. The combo hit a 36% objective response rate in patients with CPS ≥1, compared with a 19% historical response for pembrolizumab alone. Median overall survival clocked in at 39.3 months, with a safety profile similar to standard care. For a micro-cap like PDSB, having data in a top-tier journal with clear outperformance over a historical benchmark is a major de-risking event for the PDS0101 platform.

But PDSB is not positioning PDS0101 as the whole story. Management says the company is prioritizing its IL-12 immunocytokine PDS0301 in metastatic colorectal cancer, one of the toughest solid tumors to treat. PDSB is seeking a partner or potential out-license for PDS0101 instead of trying to shoulder late-stage costs alone. That adds upside optionality but also timeline and deal-structure uncertainty that traders need to factor into their thesis.

Then comes the money. PDSB closed a PIPE led by Nant Capital, raising about $11.3M at roughly $0.28 per unit, with warrants attached and another ~$11M possible if a Phase 3 protocol for PDS0301 is submitted. That pricing is brutally dilutive compared with where PDSB is trading now, which is why the stock initially dropped more than 8% when the deal was announced. Still, the financing was a lifeline for a company with negative equity and tight liquidity.

The strategic angle is what keeps traders hooked. NantWorks received a one-year exclusive option to negotiate a PDS0101 license, and heavyweight biotech figure Patrick Soon-Shiong plus NantBio CFO James Banaag have joined the PDS Biotechnology board. Add the new Schedule 13D showing a sizable holder in PDSB, and you have a stock where sophisticated capital clearly sees something worth betting on.

Conclusion

For active traders, PDSB is a classic high-risk, high-reward biotech setup. On one side, you have peer-reviewed Phase 2 PDS0101 data in JAMA Oncology, a 36% response rate versus a 19% benchmark, and nearly 40 months of median overall survival in a tough head and neck cancer setting. On the other side, you have a fragile balance sheet, heavy dilution at $0.28 with warrants, and a pipeline strategy that leans heavily on securing a partner for PDS0101 while pushing PDS0301 toward Phase 3.

The presence of Nant Capital, NantWorks’ PDS0101 option, and Patrick Soon-Shiong on the PDS Biotechnology board gives PDSB a strategic halo that many tiny biotechs never get. The Schedule 13D filing adds another layer, signaling that an active or activist-style holder is building a meaningful stake. But none of that cancels out financing risk or clinical execution risk. For PDSB, every trial update, partnership headline, or capital move can flip sentiment fast.

This is why PDSB has turned into a trading classroom in real time. The stock ripped from under $1 to above $1.70 as headlines hit, with intraday volatility offering clean setups for prepared traders. As Tim Sykes likes to say, “Volatility is opportunity if you’re prepared, but a disaster if you’re lazy.” As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” With PDSB, that means studying the JAMA data, understanding the Nant Capital deal terms, watching the 13D holder, and always being ready to cut losses fast. This coverage is strictly for educational and research purposes, and every trader has to decide for themselves how to handle a name this speculative.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!